Initial worsening following initiation of rituximab therapy in patients with cryoglobulinemic vasculitis was described in 3.6% of cases. This worsening is often a serious condition, with high levels of mortality.

The objective of our study is to evaluate the efficacy of preventive plasmapheresis prior to the introduction of rituximab performed in Montpellier France since 2013 by assessing the frequency and severity of this flare effect in these patients compared to those reported in the literature.

Inclusion criteria:

• cryoglobulinemic vasculitis requiring rituximab treatment
• Patient ≥18 years old

Exclusion Criteria:

• Patient who reject the study protocol
• Patient < 18 years old

Adult patient with cryoglobulinemic vasculitis requiring rituximab treatment

NC